Table 3. CF Peptides Presented in Significantly Different Levels between Pancreatic Cancer and Chronic Pancreatitisa.
accession no. | protein name | CF peptideb | N/SR | CP/SR | PC/SR |
---|---|---|---|---|---|
P54289 | Voltage-dependent calcium channel subunit alpha-2/delta-1 |
DDLDPEKn*DSEPGSQR | 1.13 ± 1.01 | 1.16 ± 0.42 | 0.70 ± 0.15d |
Q9BXJ4 | Complement C1q tumor necrosis factor |
TGTVDn*NTSTDLK | 9.88 ± 0.42 | 1.45 ± 0.55c | 0.83 ± 0.25d |
Q12913 | Receptor-type tyrosine-protein phosphatase eta |
Sn*DTAASEYK | 0.85 ± 0.25 | 1.26 ± 0.26c | 0.85 ± 0.26d |
P01023 | Alpha-2-macroglobulin | GNEANYYSn*ATTDEHGLVQFSIn*TTNVMGTSLTVR | 1.14 ± 0.49 | 1.88 ± 0.34c | 1.04 ± 0.39d |
Q7Z7G0 | Target of Nesh-SH3 | En*GSFSGK | 0.80 ± 0.27 | 1.24 ± 0.20c | 0.85 ± 0.19d |
P16112 | Aggrecan | TVYLYPn*QTGLPDPLSR | 0.91 ± 0.29 | 1.25 ± 0.39 | 0.83 ± 0.14d |
P58215 | Lysyl oxidase homologue 3 | n*ITAEDCSHSQDAGVR | 0.88 ± 0.41 | 0.75 ± 0.30 | 1.19 ± 0.19d |
P12111 | Collagen alpha-3(VI) chain | VAVVQHAPSESVDn*ASMPPVK | 0.93 ± 0.24 | 1.34 ± 0.31c | 0.99 ± 0.20d |
P20023 | Complement receptor type 2 | TPNGn*HTGGNIAR | 0.87 ± 0.30 | 1.10 ± 0.30c | 0.57 ± 0.34d |
P13591 | Neural cell adhesion molecule 1 |
n*ISSEEK | 1.05 ± 0.43 | 1.26 ± 0.44c | 0.89 ± 0.32d |
Q13477 | Mucosal addressin cell adhesion molecule 1 | n*ASLSAAGTR | 1.13 ± 0.50 | 1.76 ± 0.72c | 0.94 ± 0.20d |
P14151 | L-selectin | IGGIWTWVGTn*K(SL) | 1.09 ± 0.41 | 1.15 ± 0.27c | 0.90 ± 0.29d |
P01011 | Alpha-1-antichymotrypsin | LINDYVKn*GTR | 0.53 ± 0.38 | 1.41 ± 0.64c | 0.91 ± 0.39cd |
Data represent the mean and SD value based on the reporter ion ratios for CF proteins quantified in at least 5 sample sets. Significant difference level P ≤ 0.05; N, healthy controls; CP, chronic pancreatitis; PC, pancreatic cancer; SR, standard reference.
Asterisk (*) indicates CF modification at asparagine (n) residue.
Difference between healthy controls and pancreatic cancer or chronic pancreatitis.
Difference between pancreatic cancer and chronic pancreatitis.